Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism
Although rare in children, venous thromboembolism (VTE) is markedly more likely in hospitalized patients, particularly with the use of central venous access devices. Dabigatran etexilate (Pradaxa®) is one of the first direct non-vitamin K antagonist oral anticoagulants (DOAC) approved for use in ped...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis
2022
|
| Online Access: | View Fulltext in Publisher |